CYTRX CORP
S-1, EX-27.4, 2000-06-21
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Previous: CYTRX CORP, S-1, EX-27.3, 2000-06-21
Next: CYTRX CORP, S-1, EX-27.5, 2000-06-21



<TABLE> <S> <C>

<PAGE>

<ARTICLE> 5
<RESTATED>

<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-2000
<PERIOD-START>                             JAN-01-2000
<PERIOD-END>                               MAR-31-2000
<CASH>                                       3,219,486
<SECURITIES>                                         0
<RECEIVABLES>                                  390,951
<ALLOWANCES>                                         0
<INVENTORY>                                      5,142
<CURRENT-ASSETS>                             3,746,392
<PP&E>                                       3,184,380
<DEPRECIATION>                               (568,022)
<TOTAL-ASSETS>                               6,423,728
<CURRENT-LIABILITIES>                        2,022,843
<BONDS>                                              0
                                0
                                          0
<COMMON>                                        10,214
<OTHER-SE>                                   4,390,671
<TOTAL-LIABILITY-AND-EQUITY>                 6,423,728
<SALES>                                        100,128
<TOTAL-REVENUES>                               350,542
<CGS>                                                0
<TOTAL-COSTS>                                   52,420
<OTHER-EXPENSES>                             1,238,026
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                              (939,904)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                          (939,904)
<DISCONTINUED>                                  39,814
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 (900,090)
<EPS-BASIC>                                      (.11)
<EPS-DILUTED>                                    (.11)


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission